The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Open accessAbstract
Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.Methods In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered with ClinicalTrials.gov, number NCT02213926.Findings From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1-2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).Interpretation Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population.Funding Acerta Pharma, a member of the AstraZeneca Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, ibrutinib and the more selective BTK inhibitor acalabrutinib 39 have shown beneficial effects in patients with MCL and have received US Food and Drug Administration approval for this indication.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558
Barf, T. A., Covey, T. M., Izumi, R. E., van de Kar, B., Gulrajani, M., van Lith, B., Hoek, M. E.-V., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 399
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 276
Cited by
Sorted by citations
Items 101–200 of 461
Good, L., Benner, B. N., & Carson, W. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02908-5 · Cited by 39
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M. A., Sanderson, R., Menon, G., Iyengar, S., Lewis, D. J., Lambert, J., Linton, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19131 · Cited by 36
Stanchina, M., Montoya, S., Danilov, A. V., Castillo, J. J., Alencar, A. J., Chavez, J. C., Cheah, C. Y., CHIATTONE, C. S., Wang, Y., Thompson, M. C., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00956-1 · Cited by 40
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Rule, S. A., Cook, G., Russell, N. H., Hunter, A., Robinson, S. P., Morley, N. J., Sureda, A. M., Patrick, P., Clifton‐Hadley, L., Adedayo, T., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15723 · Cited by 36
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
Jiang, C., Liu, Y., Lian, J., Huang, S., Jordan, A. A., Cai, Q., Lin, R., Yan, F., McIntosh, J. M., Li, Y., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165694 · Cited by 37
Zhang, T., Harrison, M. R., O’Donnell, P. H., Alva, A. S., Hahn, N. M., Appleman, L. J., Cetnar, J. P., Burke, J. M., Fleming, M. T., Milowsky, M. I., et al. (2020) · Cancer · doi:10.1002/cncr.33067 · Cited by 35
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives
Dumont, M., Battistella, M., Ram‐Wolff, C., Bagot, M., & de Masson, A. (2020) · Cancers · doi:10.3390/cancers12061497 · Cited by 35
New Means and Challenges in the Targeting of BTK
Nawaratne, V., Sondhi, A. K., Abdel-Wahab, O. I., & Taylor, J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0409 · Cited by 37
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Haydu, J. E., & Abramson, J. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2021004535 · Cited by 35
Deng, L., Zhou, K., Liu, L., Zhang, M., Li, Z., Ji, C., Xu, W., Liu, T., Xu, B., Wang, X., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009168 · Cited by 31
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
Klener, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184417 · Cited by 33
Acalabrutinib for mantle cell lymphoma
Witzig, T. E., & Inwards, D. J. (2019) · Blood · doi:10.1182/blood.2019852368 · Cited by 32
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma
Abramson, J. S., Ghosh, N., & Smith, S. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279043 · Cited by 31
Zhang, Z., Zhang, D., Liu, Y., Yang, D., Ran, F., Wang, M. L., & Zhao, G. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201700369 · Cited by 33
Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
Rhea, I. B., Lyon, A. R., & Fradley, M. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0797-z · Cited by 30
Impact of B‐cell‐targeted therapies on cardiovascular disease
Porsch, F., & Binder, C. J. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311996 · Cited by 29
Current targeted therapies in lymphomas
Chung, C. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz202 · Cited by 29
Sawalha, Y., Goyal, S., Switchenko, J. M., Romancik, J. T., Kamdar, M. K., Greenwell, I. B., Hess, B. T., Isaac, K. M., Portell, C. A., Garcia, A. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008916 · Cited by 29
Shinoda, H., & Seto, H. (1985) · PubMed · Cited by 29
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Burkart, M., & Karmali, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030376 · Cited by 28
Eyre, T. A., Shah, N. N., Dreyling, M. H., Jurczak, W. J., Wang, Y., Cheah, C. Y., Song, Y., Gandhi, M. D., Chay, C. H., Sharman, J. P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0976 · Cited by 28
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
Yoon, D. H., Cao, J., Chen, T., Izutsu, K., Kim, S. J., Kwong, Y., Lin, T. Y., Thye, L. S., Xu, B., Yang, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00855-9 · Cited by 27
Jain, N. K., Mamgain, M., Chowdhury, S. M., Jindal, U., Sharma, I., Sehgal, L., & Epperla, N. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01496-4 · Cited by 27
Danilov, A. V., & Persky, D. O. (2020) · British Journal of Haematology · doi:10.1111/bjh.17184 · Cited by 25
Use of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 26
Guo, X., Yang, D., Fan, Z., Zhang, N., Zhao, B., Huang, C., Wang, F., Ma, R., Meng, M., & Deng, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.035 · Cited by 24
Rule, S. A., Cartron, G., Fegan, C., Morschhauser, F., Han, L., Mitra, S. S., Salles, G. A., & Dyer, M. J. S. (2019) · Leukemia · doi:10.1038/s41375-019-0658-7 · Cited by 24
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Castellino, A., Wang, Y., Larson, M. C., Maurer, M. J., Link, B. K., Farooq, U., Feldman, A. L., Syrbu, S., Habermann, T. M., Paludo, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005715 · Cited by 25
Mantle cell lymphoma: therapeutic options in transplant-ineligible patients
Robak, T., Smolewski, P., Robak, P. J., & Dreyling, M. H. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1605511 · Cited by 24
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Kallam, A., & Vose, J. M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.598 · Cited by 26
Glimelius, I. C., Smedby, K. E. E., Eloranta, S., Jerkeman, M., & Weibull, C. E. (2019) · British Journal of Haematology · doi:10.1111/bjh.16317 · Cited by 23
Chu, X., Bu, Y., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785855 · Cited by 24
Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Munoz, J. L., Wang, Y., Jain, P., & Wang, M. L. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221093980 · Cited by 23
Telford, C., Kabadi, S., Abhyankar, S. S., Song, J., Signorovitch, J., Zhao, J., & Yao, Z. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.09.012 · Cited by 22
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Fotiou, D., & Dimopoulos, M. A. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989586 · Cited by 23
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
Bond, D. A., Martin, P., & Maddocks, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061207 · Cited by 24
Rampotas, A., Wilson, M. R., Lomas, O., Denny, N., Leary, H., Ferguson, G., McKay, P., Ebsworth, T., Miller, J. L., Shah, N., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17513 · Cited by 21
Karmali, R., Switchenko, J. M., Goyal, S., Shanmugasundaram, K., Churnetski, M. C., Kolla, B. C., Bachanová, V., Gerson, J. N., Barta, S. K., Gordon, M. J., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26306 · Cited by 22
Gouill, S. L., Długosz‐Danecka, M., Rule, S. A., Zinzani, P. L., Goy, A. H., Smith, S. D., Doorduijn, J. K., Panizo, C., Shah, B. D., Davies, A. J., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282469 · Cited by 23
Treatment of relapsed/refractory MCL
Silkenstedt, E., & Dreyling, M. H. (2024) · Blood · doi:10.1182/blood.2023022353 · Cited by 24
High-risk MCL: recognition and treatment
Jain, P., & Wang, M. L. (2024) · Blood · doi:10.1182/blood.2023022354 · Cited by 23
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
Strati, P., de Vos, S., Ruan, J., Maddocks, K. J., Flowers, C. R., Rule, S. A., Patel, P. S., Xu, Y., Wei, H., Frigault, M. M., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278654 · Cited by 21
Infante, M. S., Fernández‐Cruz, A., Núñez, L., Carpio, C. D. C., Ubieto, A. J., López‐Jiménez, J., Vásquez, L., Campo, R. D., Romero, S., Alonso, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4293 · Cited by 20
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
Munoz, J. L., Wang, Y., Jain, P., & Wang, M. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01286-0 · Cited by 21
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Saleh, K., Cheminant, M., Chiron, D., Burroni, B., Ribrag, V., & Sarkozy, C. (2022) · Cancers · doi:10.3390/cancers14133229 · Cited by 22
Reagan, P. M., & Friedberg, J. W. (2021) · Future Oncology · doi:10.2217/fon-2020-0291 · Cited by 21
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
Kueffer, L. E., Joseph, R. E., & Andreotti, A. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655489 · Cited by 22
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
Jerkeman, M., Aurer, I., Campo, E., Cheah, C. Y., Clark, J., Doorduijn, J. K., Eyre, T. A., Fehr, M., Giné, E., da Silva, M. G., et al. (2025) · HemaSphere · doi:10.1002/hem3.70233 · Cited by 24
Kaplan, L. D., Maurer, M. J., Stock, W., Bartlett, N. L., Fulton, N. C., Pettinger, A. M., Byrd, J. C., Blum, K. A., LaCasce, A. S., Hsi, E. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25783 · Cited by 20
Bond, D. A., & Maddocks, K. J. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.007 · Cited by 20
Heat Shock Proteins in Lymphoma Immunotherapy
Albakova, Z., Mangasarova, Y., & Sapozhnikov, A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660085 · Cited by 22
Jerkeman, M., Kolstad, A., Hutchings, M., Pasanen, A., Meriranta, L., Niemann, C. U., Jørgensen, R. R. K., El‐Galaly, T. C., Riise, J., Leppä, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011920 · Cited by 20
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Yan, F., Jiang, C., Jordan, A. A., Che, Y., Liu, Y., Cai, Q., Xue, Y., Li, Y., McIntosh, J. M., Chen, Z., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00484-9 · Cited by 20
Ning, M. S., Pinnix, C. C., Chapman, B. V., Gunther, J. R., Milgrom, S. A., Khoury, J. D., Jain, P., Chen, W. Y., Oriabure, O., Badillo, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019030858 · Cited by 20
Morschhauser, F., Bouabdallah, K., Stilgenbauer, S., Thiéblemont, C., de Guibert, S., Zettl, F., Gelbert, L. M., Turner, P. K., Kambhampati, S. R. P., Li, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.224535 · Cited by 19
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma
López, C., Silkenstedt, E., Dreyling, M. H., & Beà, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011763 · Cited by 23
Immune cell-mediated features of atherosclerosis
Liu, T., Chen, Y., Hou, L., Yu, Y., Ma, D., Jiang, T., & Zhao, G. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1450737 · Cited by 24
Edlund, H., Lee, S. K., Andrew, M. A., Slatter, J. G., Aksenov, S., & Al-Huniti, N. H. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0725-7 · Cited by 19
Lenalidomide for the treatment of mantle cell lymphoma
Morabito, F., Skafi, M., Recchia, A. G., Kashkeesh, A., Hindiyeh, M. Y., Sabatleen, A., Morabito, L., Al‐Janazreh, H., Hamamreh, Y., & Gentile, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561865 · Cited by 19
Sathyanarayanan, V., Flowers, C. R., & Iyer, S. P. (2020) · JCO Global Oncology · doi:10.1200/go.20.00012 · Cited by 18
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z., Baghbanzadeh, A., Nakhlband, A., Baradaran, B., Jafari, S., Bagheri, Y., Raei, F., Montazersaheb, S., & Farahzadi, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120809 · Cited by 20
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation
Gambril, J. A., Ghazi, S. M., Sansoterra, S. A., Ferdousi, M., Kola-Kehinde, O. O., Ruz, P., Kittai, A. S., Rogers, K. A., Grever, M. R., Bhat, S. A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02334-3 · Cited by 18
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
Tbakhi, B., & Reagan, P. M. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221080738 · Cited by 18
Novel treatments in B cell non-Hodgkin’s lymphomas
Sawalha, Y., & Maddocks, K. J. (2022) · BMJ · doi:10.1136/bmj-2020-063439 · Cited by 19
Castellino, A., Tun, A. M., Wang, Y., Habermann, T. M., King, R. L., Ristow, K. M., Cerhan, J. R., Inwards, D. J., Paludo, J., Ansell, S. M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00394-z · Cited by 17
Spriano, F., Tarantelli, C., Gaudio, E., Gerlach, M. M., Priebe, V., Cascione, L., Bernasconi, E., Targa, A., Mascia, M., Dirnhofer, S., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16118 · Cited by 17
Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Pineda-Gayoso, R., Alomar, M., Lee, D. H., & Fradley, M. G. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00764-6 · Cited by 17
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson, J. N., Handorf, E. A., Villa, D. R., Gerrie, A. S., Chapani, P., Li, S., Medeiros, L. J., Wang, M. L., Cohen, J. B., Churnetski, M. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010757 · Cited by 16
Hoang, N.-M., Liu, Y., Bates, P. D., Heaton, A. R., Lopez, A. F., Liu, P., Zhu, F., Chen, R., Kondapelli, A., Zhang, X., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101484 · Cited by 20
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Maaland, A. F., Heyerdahl, H., O’Shea, A., Eiríksdóttir, B., Pascal, V., Andersen, J. T., Kolstad, A., & Dahle, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04417-1 · Cited by 16
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
Low, J., & Peters, K. B. (2020) · CNS Oncology · doi:10.2217/cns-2019-0022 · Cited by 16
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Makita, S., Hosoba, R., & Tobinai, K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1802424 · Cited by 17
Tarantelli, C., Zhang, L., Curti, E., Gaudio, E., Spriano, F., Priebe, V., Cascione, L., Arribas, A. J., Zucca, E., Rossi, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214759 · Cited by 16
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
Eyre, T. A., Cheah, C. Y., Sarkozy, C., Kumar, A. A., & Gouill, S. L. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00146 · Cited by 18
Yu, H., Truong, H., Mitchell, S. A., Liclican, A. C., Gosink, J. J., Li, W., Lin, J. H., Feng, J. Y., Jürgensmeier, J. M., Billin, A. N., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218786165 · Cited by 15
Robak, P. J., Witkowska, M., Wolska, A., & Robak, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2236547 · Cited by 15
Current trials for frontline therapy of mantle cell lymphoma
Steiner, R. E., Romaguera, J. E., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0556-x · Cited by 15
Rodgers, T. D., & Reagan, P. M. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1479396 · Cited by 16
Sandoval-Sus, J. D., Faramand, R. G., Chávez, J. C., Puri, S., Parra, P., Sokol, L., Kharfan‐Dabaja, M. A., Shah, B. D., & Ayala, E. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1468894 · Cited by 15
Chávez, J. C., Yassine, F., Sandoval-Sus, J. D., & Kharfan‐Dabaja, M. A. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2020-0021 · Cited by 16
Zhang, H., Ou, Y. C., Su, D., Wang, F., Wang, L., Sahasranaman, S., & Tang, Z. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.870 · Cited by 15
Sawalha, Y., Bond, D. A., & Alinari, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s238832 · Cited by 15
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 17
Mantle cell lymphoma management trends and novel agents: where are we going?
Pu, J. J., Savani, M., Huang, N., & Epner, E. M. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221080743 · Cited by 15
Bravo-González, A., Alasfour, M., Soong, D., Noy, J., & Pongas, G. N. (2024) · Cancers · doi:10.3390/cancers16203434 · Cited by 14
Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents
Spadafora, L., Russo, F., Bukowska‐Olech, E., Panichella, G., Garofalo, M., Cacciatore, S., Sabouret, P. F., Sarto, G., Simeone, B., Rocco, E., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00757-6 · Cited by 16
Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review
Luttwak, E., Gurevich‐Shapiro, A., Azem, F., Lishner, M., Klieger, C., Herishanu, Y., Perry, C., & Avivi, I. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100831 · Cited by 14
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
Παπανώτα, Α.-Μ., Ntanasis‐Stathopoulos, I., Kastritis, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s183997 · Cited by 14
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
Kumar, S. A., Gao, J., & Patel, S. A. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107385 · Cited by 13
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
Delgado, J., Josephson, F., Camarero, J., Garcia-Ochoa, B., López‐Anglada, L., Prieto-Fernández, C., van Hennik, P. B., Papadouli, I., Gisselbrecht, C., Enzmann, H. G., et al. (2021) · The Oncologist · doi:10.1002/onco.13685 · Cited by 13
Jiang, D. L., Song, Z., Hu, Y., Dong, F., & Zhao, R. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2106968 · Cited by 13
Barachini, S., Buda, G., & Petrini, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061574 · Cited by 16
Fu, S., Wang, M. L., Li, R., Lairson, D. R., Zhao, B., & Du, X. L. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.12.002 · Cited by 12
Zhang, J., Zhao, X., Yang, C., Huang, Z., Shi, M., Pan, S., Hu, H., Qiao, M., Chen, D., & Zhao, X. (2019) · Biomaterials Science · doi:10.1039/c9bm00812h · Cited by 12
Loss of BTK ameliorates the pathological cardiac fibrosis and dysfunction
Wang, B., Tan, Y. C., Zhou, W., Yang, J., Jiang, Y., Liu, X., & Zhan, Z. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.08.010 · Cited by 12
Zinzani, P. L., Trněný, M., Ribrag, V., Zilioli, V. R., Walewski, J. A., Christensen, J. H., Delwail, V., Rodriguez, G., Venugopal, P., Coleman, M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102131 · Cited by 12
Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma
Bukhari, A. A., & Lee, S. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1676717 · Cited by 12
Arcos, I. L., & Ruíz-Camps, I. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.07.026 · Cited by 12
The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma
Hanna, K. S., Campbell, M., Husak, A., & Sturm, S. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220915956 · Cited by 12
Metadata
- Authors
- Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., Covey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G., & Jurczak, W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Plymouth (GB)
- University of Bologna (IT)
- Hackensack University Medical Center (US)
- Inserm (FR)
- University of Washington (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Erasmus MC (NL)
- Centre Hospitalier Universitaire de Rennes (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Clinica Universidad de Navarra (ES)
- Moffitt Cancer Center (US)
- Cancer Research UK (GB)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Jagiellonian University (PL)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 391
- Issue
- 10121
- Pages
- 659-667
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7864374
- OpenAlex
- W2774522106
- Cited by
- 453
- References
- 23
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 51 · 2023: 49 · 2022: 59 · 2021: 60 · 2020: 63 · 2019: 64 · 2018: 34
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- PEARL (University of Plymouth) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- ePrints Soton (University of Southampton) (submittedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- AstraZeneca
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- acalabrutinib, mantle cell lymphoma, relapsed/refractory lymphoma, BTK inhibitors, overall response rate, complete response, progression-free survival, overall survival, adverse events, neutropenia, drug safety, oral targeted therapy, treatment durability, hemorrhage
- MeSH terms
- Aged, Benzamides, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pyrazines, Recurrence, Survival Analysis, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
